2015
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio M, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy M, Hoang-Xuan K. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. The Lancet Haematology 2015, 2: e251-e259. PMID: 26688235, DOI: 10.1016/s2352-3026(15)00074-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCytarabineDacarbazineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineProspective StudiesQuality of LifeTemozolomideTreatment OutcomeVincristineConceptsPrimary CNS lymphomaProgression-free survivalKarnofsky Performance Scale scoreCytarabine groupPhase 2 trialCNS lymphomaPerformance Scale scoreTemozolomide groupElderly populationScale scoreMedian progression-free survivalPhase 2 trial designCommon grade 3Methotrexate-based regimensProphylactic G-CSFMedian overall survivalStandard chemotherapy regimenPoor prognosis patientsQuality of lifeChemotherapy regimenEfficacy endpointPrimary endpointPrognosis patientsElderly patientsImmunocompetent patientsFirst-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
Kasenda B, Ferreri A, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Hoang-Xuan K, Pulczynski E, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor T, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Annals Of Oncology 2015, 26: 1305-1313. PMID: 25701456, PMCID: PMC4735103, DOI: 10.1093/annonc/mdv076.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreElderly PCNSL patientsFirst-line therapyHD-MTXIndividual patient dataPCNSL patientsImproved survivalEligible studiesElderly primary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaSystematic reviewCentral nervous system lymphomaHigh-dose methotrexatePatient dataWhole brain radiotherapyFirst-line treatmentNervous system lymphomaStrong prognostic factorElderly patientsImmunocompetent patientsProspective trialMedian ageOral chemotherapyPrognostic factors
2013
Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study.
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Maire J, Benouaich Amiel A, Lebouvier-Sadot S, Gyan E, Barrie M, Sierra del Rio M, Gonzalez A, Houillier C, Tanguy M, Hoang-Xuan K. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study. Journal Of Clinical Oncology 2013, 31: 2032-2032. DOI: 10.1200/jco.2013.31.15_suppl.2032.Peer-Reviewed Original ResearchPrimary CNS lymphomaAbnormal liver function testsCycles of methotrexateProphylactic G-CSFWhole brain radiotherapyLiver function testsPhase II trialProspective multicenter studyBaseline cognitive impairmentQuality of lifePre-treatment characteristicsCommon toxicitiesCytarabine consolidationCNS lymphomaEfficacy endpointII trialPrimary endpointBrain radiotherapyElderly patientsObjective responseStandard chemotherapyCR rateFunction testsIntergroup studyMulticenter study
2012
First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis
Kasenda B, Ferreri A, Maturano E, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Xuan K, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Gloy V, Bhatnagar N, Haug S, Rahner S, Illerhaus G, Briel M. First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis. Blood 2012, 120: 3655. DOI: 10.1182/blood.v120.21.3655.3655.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaIndividual patient dataCentral nervous system lymphomaElderly PCNSL patientsMedian age 68Improved overall survivalFirst-line treatmentNervous system lymphomaOverall survivalElderly patientsPCNSL patientsSystematic reviewEligible studiesPerformance statusSystem lymphomaFunctional statusAge 68Patient dataBetter outcomesIndividual Patient Data Meta-AnalysisDifferent first-line treatmentsMultivariable Cox regression modelsFollowing baseline characteristicsImmunocompetent PCNSL patientsCo-morbidity index
2010
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma
Ducray F, Sierra del Rio M, Carpentier C, Psimaras D, Idbaih A, Dehais C, Kaloshi G, Mokhtari K, Taillibert S, Laigle-Donadey F, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. Journal Of Neuro-Oncology 2010, 101: 457-462. PMID: 20556480, DOI: 10.1007/s11060-010-0264-z.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, AlkylatingBrain NeoplasmsDacarbazineDNA MethylationDNA Modification MethylasesDNA Repair EnzymesDNA, NeoplasmFemaleFollow-Up StudiesHumansMaleOligodendrogliomaPolymerase Chain ReactionPromoter Regions, GeneticRetrospective StudiesSurvival RateTemozolomideTreatment OutcomeTumor Suppressor ProteinsConceptsProgression-free survivalAnaplastic oligodendroglial tumorsElderly patientsOverall survivalFront chemotherapyPartial responseMedian progression-free survivalLonger progression-free survivalInitial radiation therapyLonger overall survivalDuration of responseRate of respondersO6-methylguanine-DNA methyltransferase (MGMT) promoter methylationMethyltransferase promoter methylationEvaluable patientsStable diseaseConsecutive patientsConventional dosesRetrospective studyOptimal treatmentAnaplastic oligodendrogliomaRadiation therapyPatientsOligodendroglial tumorsTumor progressionMulticenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients.
Omuro A, Taillandier L, Chinot O, Ghesquieres H, Soussain C, Delwail V, Choquet S, Tanguy M, Lamy T, Hoang-Xuan K. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients. Journal Of Clinical Oncology 2010, 28: tps144-tps144. DOI: 10.1200/jco.2010.28.15_suppl.tps144.Peer-Reviewed Original Research
2007
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Journal Of Neuro-Oncology 2007, 85: 207-211. PMID: 17896079, DOI: 10.1007/s11060-007-9397-0.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaIntra-thecal chemotherapyFavorable toxicity profileComplete responseToxicity profilePrimary central nervous system lymphomaMedian event-free survivalCentral nervous system lymphomaMedian overall survivalEvent-free survivalNervous system lymphomaNew alternative treatmentLow response rateInduction chemotherapyInnovative regimenCNS lymphomaElderly patientsIntestinal obstructionOverall survivalPCNSL patientsYounger patientsSystem lymphomaConsecutive seriesEfficacy resultsGrade 3
2006
Chemotherapy for primary central nervous system lymphoma.
Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurgical FOCUS 2006, 21: e12. PMID: 17134114, DOI: 10.3171/foc.2006.21.5.13.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaHigh-dose methotrexateUse of chemotherapyNervous system lymphomaElderly patientsSystem lymphomaSuch elderly patientsMainstay of treatmentToxic regimensChemotherapy regimensCorticosteroid agentsYounger patientsPatient ageRelapse rateRandomized trialsDifferent regimensOptimal treatmentRecent trialsTreatment paradigmHigh riskChemotherapyEffective drugsSingle agentRegimens